drugset / Trial / NCT05110768

Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy

NCT05110768

Phase 2 Unknown 75 enrolled Rockwell Medical Technologies, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose is to determine whether FPC, administered via infusion, is safe and effective for the treatment of iron deficiency anemia (IDA) in patients receiving Home Infusion therapies (HI).

Timeline

Start
2021-11-30
Primary completion
2022-04-30
Completion
2022-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Triferic Other / unclassified 20 mg Intravenous